Alteration of the Tumor Suppressor Gene p53 in a High Fraction of Hormone Refractory Prostate Cancer

No AccessJournal of UrologyClinical Urology: Original Article1 Aug 1995Alteration of the Tumor Suppressor Gene p53 in a High Fraction of Hormone Refractory Prostate Cancer Howard B. Heidenberg, Isabell A. Sesterhenn, Jaya P. Gaddipati, Christopher M. Weghorst, Gregory S. Buzard, Judd W. Moul, and Shiv* Srivastava Howard B. HeidenbergHoward B. Heidenberg , Isabell A. SesterhennIsabell A. Sesterhenn , Jaya P. GaddipatiJaya P. Gaddipati , Christopher M. WeghorstChristopher M. Weghorst , Gregory S. BuzardGregory S. Buzard , Judd W. MoulJudd W. Moul , and Shiv* SrivastavaShiv* Srivastava View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)67065-4AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We studied the role of p53 tumor suppressor gene alteration in prostate cancer progression by demonstrating a difference in abnormal p53 findings between early and hormone refractory disease. Materials and Methods: The study included p53 immunohistochemistry of 26 archival transurethral resection specimens from patients with radiation recurrent and hormone refractory disease, 27 untreated primary tumors and 8 untreated metastatic lesions. p53 mutation analysis of tumor deoxyribonucleic acid (DNA) from microdissected specimens was done by cold single strand conformational polymorphism and DNA sequencing. Results: Elevated p53 protein was present in 16 of 17 hormone refractory specimens (94 percent), 4 of 8 untreated metastatic tumors (50 percent) and 6 of 27 primary untreated tumors (22 percent). DNA analysis of representative specimens with elevated p53 confirmed p53 gene alterations in 9 of 11 cases (82 percent). Conclusions: Our study revealed a clear progression of increased p53 alteration from untreated primary to hormone refractory disease (p less than 0.00005). References 1 : Cancer statistics, 1993. CA1993; 43: 7. Google Scholar 2 : New prognostic factors in prostatic carcinoma. Eur. Urol.1993; 24: 438. Google Scholar 3 : Grading of prostatic carcinoma. Cancer Chemother. Rep.1975; 59: 111. Google Scholar 4 : Mutations in the p53 tumor suppressor gene, clues to cancer etiology and molecular pathogenesis. Cancer Res.1994; 54: 4855. Google Scholar 5 : Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science1990; 250: 1233. Google Scholar 6 : Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature1990; 348: 747. Google Scholar 7 : Cancer risks from germline p53 mutations. J. Clin. Invest.1992; 90: 1637. Google Scholar 8 : p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res.1993; 53: 3369. Google Scholar 9 : Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J. Natl. Cancer Inst.1992; 84: 883. Google Scholar 10 : Comparative analysis of p53 protein immunoreactivity in prostatic, lung and breast carcinomas. Virchows Arch. Path. Anat. Histopath.1992; 421: 223. Google Scholar 11 : p53 c-erbB-2 and epidermal growth factor receptor in the benign and malignant prostate. J. Urol.1992; 147: 496. Abstract, Google Scholar 12 : p53 oncogene mutations in human prostate cancer specimens. J. Urol.1994; 151: 492. Link, Google Scholar 13 : p53 gene alterations in human prostate carcinoma. J. Urol.1993; 150: 257. Abstract, Google Scholar 14 : p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J. Natl. Cancer Inst.1993; 85: 1657. Google Scholar 15 : Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. J. Urol.1994; 151: 1276. Abstract, Google Scholar 16 : Histological grading and clinical staging of prostate carcinoma. In: Urologic Pathology: The Prostate. Edited by . Philadelphia: Lea & Febiger1977: 171. Google Scholar 17 : Histological Typing of Prostate Tumours. Geneva: World Health Organization1980. Google Scholar 18 : Update in staging systems. In: . London: Springer-Verlag1987: 107. chapt. 6. Google Scholar 19 : Infrequent RAS oncogene mutations in human prostate cancer. Prostate1992; 20: 327. Google Scholar 20 : 'Cold SSCP': a simple, rapid and non-radioactive method for optimized single-strand conformation polymorphism analyses. Nucleic Acids Res.1993; 21: 3637. Google Scholar 21 : Detection of both mutant and wild-type p53 protein in normal skin fibroblasts and demonstration of a shared 'second hit' on p53 in diverse tumors from a cancer-prone family with Li-Fraumeni syndrome. Oncogene1992; 7: 987. Google Scholar 22 : Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res.1994; 54: 2861. Medline, Google Scholar 23 : Mutuant p53 expression in prostate carcinoma. Prostate1993; 22: 23. Google Scholar 24 : p53 mutant expression correlates with hormone sensitivity and prognosis in human prostatic adenocarcinoma. J. Urol., part 21993; 149: 377A. abstract 658. Google Scholar 25 : Infrequent involvement of p53 gene mutations in the tumourigenesis of Japanese prostate cancer. Brit. J. Cancer1993; 68: 751. Google Scholar 26 : Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res.1991; 51: 4716. Google Scholar 27 : p53 and c-myc expression in stage A-1 prostatic adenocarcinoma: useful prognostic determinents?. J. Urol.1993; 150: 490. Abstract, Google Scholar 28 : p53 expression and clinical outcome in prostate cancer. Brit. J. Urol.1993; 72: 778. Google Scholar 29 : Alternations of the p53 gene are associated with the progression of a human prostate carcinoma. J. Urol.1992; 147: 789. Abstract, Google Scholar 30 : Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J. Urol., part 21994; 152: 388. Abstract, Google Scholar 31 : Accumulation of nuclear p53 and tumor progression in bladder cancer. New Engl. J. Med.1994; 331: 1259. Crossref, Medline, Google Scholar 32 : Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding. Mol. Cell Biol.1992; 12: 5581. Google Scholar 33 : Dominant negative effect of a germ-line mutant p53: a step fostering tumorigenesis. Cancer Res.1994; 53: 4452. Google Scholar 34 : Enhanced expression of p53 mRNA and protein in the regressing rat ventral prostate. Biochem. Biophys. Res. Comm.1994; 198: 1189. Google Scholar 35 : Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation. Proc. Natl. Acad. Sci.1993; 90: 8910. Google Scholar 36 : WAF1/CIP1 is induced in p53-mediated g1 arrest and apoptosis. Cancer Res.1994; 54: 1169. Google Scholar Urology Service, Departments of Surgery and Clinical Investigation, Walter Reed Army Medical Center and Department of Genitourinary Pathology, Armed Forces Institute of Pathology, Washington, D. C., and Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of Health Sciences, Laboratory of Comparative Carcinogenesis, National Cancer Institute and BCDP, PRI/Dyn Corporation, Frederick Cancer Research and Development Center, Frederick, Maryland.© 1995 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byAtala A (2016) Re: Resistance to Docetaxel in Prostate Cancer is Associated with Androgen Receptor Activation and Loss of KDM5D ExpressionJournal of Urology, VOL. 197, NO. 1, (154-155), Online publication date: 1-Jan-2017.EASTHAM J, GRAFTON W, MARTIN C and WILLIAMS B (2018) SUPPRESSION OF PRIMARY TUMOR GROWTH AND THE PROGRESSION TO METASTASIS WITH p53 ADENOVIRUS IN HUMAN PROSTATE CANCERJournal of Urology, VOL. 164, NO. 3 Part 1, (814-819), Online publication date: 1-Sep-2000.STACKHOUSE G, SESTERHENN I, BAUER J, MOSTOFI F, CONNELLY R, SRIVASTAVA S and MOUL J (2018) P53 AND BCL-2 IMMUNOHISTOCHEMISTRY IN PRETREATMENT PROSTATE NEEDLE BIOPSIES TO PREDICT RECURRENCE OF PROSTATE CANCER AFTER RADICAL PROSTATECTOMYJournal of Urology, VOL. 162, NO. 6, (2040-2045), Online publication date: 1-Dec-1999.NAVONE N, LABATE M, TRONCOSO P, PISTERS L, CONTI C, VON ESCHENBACH A and LOGOTHETIS C (2018) p53 MUTATIONS IN PROSTATE CANCER BONE METASTASES SUGGEST THAT SELECTED p53 MUTANTS IN THE PRIMARY SITE DEFINE FOCI WITH METASTATIC POTENTIALJournal of Urology, VOL. 161, NO. 1, (304-308), Online publication date: 1-Jan-1999.GROSSFELD G, OLUMI A, CONNOLLY J, CHEW K, GIBNEY J, BHARGAVA V, WALDMAN F and CARROLL P (2018) LOCALLY RECURRENT PROSTATE TUMORS FOLLOWING EITHER RADIATION THERAPY OR RADICAL PROSTATECTOMY HAVE CHANGES IN KI-67 LABELING INDEX, P53 AND BCL-2 IMMUNOREACTIVITYJournal of Urology, VOL. 159, NO. 5, (1437-1443), Online publication date: 1-May-1998.Noordzij M, Bogdanowicz J, van Krimpen C, van der Kwast T and van Steenbrugge G (2018) THE PROGNOSTIC VALUE OF PRETREATMENT EXPRESSION OF ANDROGEN RECEPTOR AND BCL-2 IN HORMONALLY TREATED PROSTATE CANCER PATIENTSJournal of Urology, VOL. 158, NO. 5, (1880-1885), Online publication date: 1-Nov-1997.Bauer J, Sesterhenn I, Mostofi F, McLeod D, Srivastava S and Moul J (2018) Elevated Levels of Apoptosis Regulator Proteins P53 and BCL-2 are Independent Prognostic Biomarkers in Surgically Treated Clinically Localized Prostate CancerJournal of Urology, VOL. 156, NO. 4, (1511-1516), Online publication date: 1-Oct-1996. Volume 154Issue 2August 1995Page: 414-421 Advertisement Copyright & Permissions© 1995 by American Urological Association, Inc.MetricsAuthor Information Howard B. Heidenberg More articles by this author Isabell A. Sesterhenn More articles by this author Jaya P. Gaddipati More articles by this author Christopher M. Weghorst More articles by this author Gregory S. Buzard More articles by this author Judd W. Moul More articles by this author Shiv* Srivastava More articles by this author Expand All Advertisement PDF downloadLoading ...